CORYFIN C 100 24CARAMELLE

CORYFIN

active ingredients

Coryfin 6.5 mg + 18 mg pills Active ingredients: ethylglyculate menthol 6,5 mg; ascorbate sodium 18,0 mg equal to 16 mg of ascorbic acid (Vitamin C). Excipients with known effects: glucose 0.9 g, sucrose 1.1 g. Coryfin 2,8 mg + 16,8 mg pills Active ingredients: ethylglyculate menthol 2.8 mg; ascorbate sodium 16.8 mg equal to 15 mg of ascorbic acid (Vitamin C). Excipients with known effects: glucose 0.9 g, sucrose 1.1 g. Coryfin 6.5 mg + 112.5 mg pills Active ingredients: ethylglyculate menthol 6.5 mg; ascorbate sodium 112.5 mg equal to 100 mg of ascorbic acid (Vitamin C). Excipients with known effects: glucose 0.8 g, sucrose 1 g. For the full list of excipients, see paragraph 6.1.

Excellent

A pastel of Coryfin 6.5 mg + 18 mg contains: menthol–eucalyptus aroma, citric acid, sucrose, glucose. A paste of Coryfin 2.8 mg + 16.8 mg contains: menthol, citric acid, lemon essence, sucrose, glucose. A pastel of Coryfin 6.5 mg + 112.5 mg contains: menthol, mandarin aroma, citric acid, sucrose, glucose.

Therapeutic indications

Syntomatic in the treatment of cough and raucedine. Coryfin relieves local irritation and reduces catarror, even in smokers.

Contraindications

– Hypersensitivity to active ingredients or any of the excipients listed in the paragraph 6.1. – Children up to 30 months of age. – Children with a history of epilepsy or fever seizures.

Population

Population Coryfin 6.5 mg + 18 mg and Coryfin 2.8 mg + 16.8 mg: A pill every 1–2 hours, up to a maximum of 8 tablets per day. Coryfin 6.5 mg + 112.5 mg: A pill every 2–3 hours, up to a maximum of 6 pads per day. Pediatric population In children over 30 months halved doses. Do not exceed the doses indicated. The duration of treatment shall not exceed 3 days.

Conservation

This medicine does not require any special condition for conservation.

Warnings

This product contains terpenic derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. The treatment should not be extended for more than 3 days for the risks associated with the accumulation of terpenic derivatives, such as canphora, cineol, niaouli, wild thyme, terpineol, terpineol, citral, menthol and essential oils of pine needles, eucalyptus and trementine (due to their lipophilic properties, it is not known the speed of metabolism and disposal) in particular tissues. A dose higher than the recommended dose should not be used to avoid greater risk of adverse reactions to the medicinal product and overdosage disorders (see paragraph 4.9). The product is flammable, it should not be approached to flames. Coryfin contains glucose. Patients suffering from rare glucose–galactose disease problems should not take this medicine. Coryfin contains sucrose. Patients with rare fructose intolerance problems, glucose–galactose mal absorption, or isomaltase sucrasis failure, should not take this medicine. To consider in people with diabetes mellitus.

Interactions

Coryfin should not be used in conjunction with other products (medicinal or cosmetic) containing terpenic derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).

Effects

In rare cases of sensitizing or irritating effects, suspend use and establish suitable therapy. Pediatric population Due to the presence of menthol and in case of non-compliance with recommended doses, a risk of seizures in children and infants may arise. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: www.agenziafarmaco.gov.it/it/responsabili.

Overdosing

No known overdose effects. Pediatric population In case of accidental oral intake or incorrect administration in infants and children, the risk of neurological disorders may arise. If necessary, administer appropriate symptomatic treatment in specialized care centers.

Pregnancy There are or are limited numbers available for the use of menthol in pregnant women. Coryfin is not recommended during pregnancy and in pregnant women who do not use contraceptive measures. Food There is insufficient information on the excretion of menthol in breast milk. Coryfin should not be used during lactation.

Source: Farmadati